Whether your mitral valve can be repaired rather than replaced — and whether a catheter-based option such as MitraClip fits your anatomy — depends heavily on the surgeon and center you reach. An independent review by a cardiac surgeon and a cardiologist defines your exact mechanism, your real risk, and the path most likely to preserve your own valve. A written review is delivered within 24 hours of your records — from $500.
Cardiac surgeon + cardiologist review · From $500 · 24-hour written review after records · No referral · HSA/FSA eligible
A mitral valve second opinion exists to answer four questions clearly and honestly. We address each one directly, in writing, signed by your Heart Team.
We confirm whether your mitral regurgitation or stenosis has reached the guideline threshold for intervention — or whether you are a candidate for active surveillance. Severity, symptoms, ventricular size and function, and atrial fibrillation all factor into whether the time for surgery has truly arrived.
For the right anatomy, transcatheter edge-to-edge repair (TEER, MitraClip) or a minimally invasive right mini-thoracotomy can treat mitral disease without a full sternotomy. We assess whether your valve and your risk profile make a catheter-based or minimally invasive approach appropriate.
We calculate your operative risk with validated models (STS-PROM, EuroSCORE II) plus a frailty assessment — and weigh it against the transcatheter alternative, so you can see the real trade-off between durability and recovery for your specific case.
Mitral repair rates and outcomes vary enormously by surgeon and center. We identify the high-volume degenerative-mitral specialists and reference centers most likely to repair rather than replace your valve — because who operates is often as important as which operation.
Mitral valve disease is uniquely sensitive to who treats it. Whether your valve is repaired, replaced, or clipped depends on your precise mechanism and on the experience of your surgeon and center. Here is what an independent review weighs.
For degenerative mitral regurgitation, repair is almost always superior to replacement — it preserves your own valve, avoids long-term anticoagulation, and delivers better long-term survival in experienced hands. The central question of any mitral second opinion is whether your valve is repairable, and whether you are being sent to a surgeon and center with a high repair rate. Posterior leaflet prolapse is highly repairable; anterior and bileaflet (Barlow) disease are more complex and benefit most from a reference-center specialist.
Transcatheter edge-to-edge repair (TEER) clips the mitral leaflets together through a catheter, with no chest incision. It is established for high-risk patients with degenerative disease and for selected patients with secondary (functional) mitral regurgitation who remain symptomatic on optimal medical therapy. TEER is not a substitute for a durable surgical repair in a low-risk, good-anatomy patient — but for the right candidate it is transformative. Anatomy (leaflet length, calcification, mitral valve area, gradient) determines feasibility.
When the valve cannot be reliably repaired — extensive calcification, rheumatic disease, infective endocarditis with destruction, or failed prior repair — replacement with a mechanical or bioprosthetic valve is the right answer. The choice between mechanical (durable, requires lifelong anticoagulation) and tissue (no long-term anticoagulation, finite lifespan) hinges on your age, bleeding risk, and preferences. A good second opinion confirms replacement is genuinely necessary before accepting it over repair.
The right strategy depends on the precise mechanism of your mitral disease (primary/degenerative vs. secondary/functional), classified by the Carpentier framework, and on your operative risk. Severe LV dysfunction, pulmonary hypertension, prior cardiac surgery, and frailty all shift the calculus between open repair, replacement, and transcatheter therapy. We define your mechanism and your numbers precisely.
Coexisting coronary disease, tricuspid regurgitation, atrial fibrillation, or aortic valve disease can change the optimal plan. A surgical approach can address several problems in one operation (for example, a concomitant Maze procedure for atrial fibrillation or tricuspid repair); transcatheter therapy generally treats one lesion at a time. We map the full picture, not just the mitral valve in isolation.
Repair rates for degenerative mitral disease range from below 50% at low-volume centers to above 95% at reference centers. The single biggest predictor of whether your valve is repaired — and repaired durably — is the surgeon and program you reach. We match your specific valve pathology to the surgeons and centers with the strongest documented mitral outcomes.
Your cardiac surgeon and cardiologist lead the review to define the optimal mitral strategy for your case.
We review your transthoracic and transesophageal echocardiograms to define the precise mechanism (Carpentier type I/II/III), leaflet segments involved, regurgitation severity, mitral valve area and gradient, and the features that predict repairability versus the need for replacement or TEER.
A focused appraisal of whether your valve is durably repairable and whether you are being directed to a surgeon and center with a high repair rate for your specific lesion — the factor most likely to change your outcome and your need for future reoperation.
Systematic evaluation of transcatheter edge-to-edge repair feasibility — leaflet anatomy, calcification, baseline mitral valve area and gradient, and primary versus secondary mechanism — to determine whether MitraClip-type therapy is an appropriate option for you.
STS-PROM for mitral repair and replacement, EuroSCORE II, and a frailty assessment calculated from your clinical data — with predicted outcomes for mortality, stroke, renal failure, prolonged ventilation, and major morbidity across the surgical and transcatheter pathways.
Your case mapped to current ACC/AHA Valvular Heart Disease guidelines, with the specific class of recommendation and level of evidence for repair, replacement, TEER, and continued surveillance based on your severity, symptoms, and ventricular metrics.
We identify degenerative-mitral specialists and reference centers with the highest volumes and best documented repair rates and outcomes for your specific mitral pathology.
Begin wherever you feel most comfortable. Every path reaches the same Heart Team.
Yes — mitral valve disease is one of the strongest cases for a second opinion in all of cardiology. Whether your valve can be repaired rather than replaced depends heavily on the surgeon and center you reach, and the difference has lifelong consequences for survival, anticoagulation, and reoperation. A second opinion confirms whether intervention is truly indicated now, whether repair is achievable, and whether a less invasive option such as TEER fits your case.
Mitral repair preserves your own valve by reconstructing it — the preferred approach for degenerative regurgitation, with the best long-term survival and no need for lifelong anticoagulation. Replacement substitutes a mechanical or tissue valve when the native valve cannot be reliably repaired. TEER (transcatheter edge-to-edge repair, such as MitraClip) clips the leaflets together through a catheter without opening the chest — established for high-risk patients and for selected secondary mitral regurgitation. The right choice depends on your mechanism, anatomy, and operative risk.
Often, yes — but it depends on your valve pathology and, critically, on your surgeon. Degenerative posterior leaflet prolapse is repairable in well over 90% of cases at high-volume centers, while repair rates are far lower at low-volume programs. Anterior leaflet and bileaflet (Barlow) disease are more complex and benefit most from a reference-center specialist. Our review assesses your specific mechanism and helps direct you to a surgeon with a high repair rate for your lesion.
TEER candidacy depends on your mitral anatomy — leaflet length and mobility, calcification, baseline mitral valve area and gradient — and on whether your regurgitation is primary (degenerative) or secondary (functional). It is well established for high-surgical-risk degenerative patients and for selected functional mitral regurgitation that remains symptomatic on optimal medical therapy. It is generally not the first choice for a low-risk patient whose valve can be durably surgically repaired. Our analysis assesses your TEER feasibility specifically.
In almost all cases, no. Your White Glove Insights™ Report is delivered within 24 hours of receiving your complete medical records, so an independent review typically fits inside the normal scheduling window before an elective mitral operation. If your situation is urgent, contact our team to discuss an expedited turnaround. We will never advise delaying genuinely time-critical surgery.
WhiteGloveMD mitral valve second opinions start at $500 for the written review, which includes full analysis, echo and TEE review, repairability and TEER candidacy assessment, multi-model risk scoring, and a dual-physician-signed White Glove Insights™ Report. Packages that add a video consultation range higher. The service is HSA/FSA eligible — visit our pricing page for full details.
Medically reviewed by Rahul R. Handa, MD — Cardiovascular & Thoracic Surgeon
Last reviewed: June 2026Get an independent Heart Team review — led by a cardiac surgeon and cardiologist — to learn whether your valve can be repaired, replaced, or treated with TEER. A written review is delivered within 24 hours of your records, from $500.